Freshmedx has reported positive results from a clinical trial of computerised bioconductance test (CB test), a lung cancer test which is used to distinguish between benign and malignant indeterminate masses.
In the trial, the CB test demonstrated 90% sensitivity and 92% specificity in distinguishing between benign and malignant masses in undiagnosed individuals with lung cancer symptoms.
The CB test is non-invasive, involves no ionising radiation and is based on characterisation of a radiologically indeterminate lung mass.
Freshmedx clinical affairs vice-president Karleen Callahan said the technology had the potential to reduce the stressful waiting period for those who have indeterminate masses and often undergo additional CT evaluation prior to receiving biopsy.
“It helps inform the physician whether an immediate biopsy is warranted or if longer term, radiological follow-up is appropriate,” Callahan added.